ANDREW (“Drew”) SENYEI, M.D., is a venture capitalist and inventor with more than 30 years of experience in the building of emerging technology and healthcare companies.
Dr. Senyei served as Managing Director of Enterprise Partners Venture Capital with $1.1B under management for 25 years. He has served on the boards of more than 30 private and public companies and was named one of the top 100 venture capitalists in the U.S. on Forbes magazine’s 2006 Midas Touch List. He was the founding investor in Nuvasive (NASDAQ: NUVA), one of the largest minimally non-invasive orthopedic companies in the U.S today with revenues of more than $1B. Currently, Dr. Senyei is Executive Chairman of, NeoSeq Ltd, a company focused on advanced genetic testing of cancer and other diseases with primary operations in mainland China.
Dr. Senyei is also actively involved with early stage angel investing in a variety of high-tech industries. He was the recipient of the 2007 Ernst & Young San Diego Master Entrepreneur Award. He is credited with 30 patents and more than 45 publications in peer-reviewed journals, including the New England Journal of Medicine and Proceedings of the National Academy of Science. He was an inventor of the first and currently only FDA approved test to predict and help manage pre-term birth which has been used by over 2 million women worldwide. His other inventions include using RF chips for new chemical compound synthesis and single cell isolation technologies for medical diagnostics.
He currently serves on The Board of Trustees at Northwestern University. Dr. Senyei is a former Chair of the UCSD Jacobs School of Engineering Advisory Council and member of UCSD Foundation Board. Currently, he is co-chair of the advisory board of the California Institute for Telecommunications and Information Technology (CALIT2). Dr. Senyei is past president of the San Diego Opera and in 2006 he won a Tony Award as one of the producers of the hit Broadway musical, Jersey Boys.
Dr. Senyei received his M.D. from Northwestern University and completed his residency training at the University of California, Irvine, where he served on the faculty prior to becoming active full-time with venture capital funding of early stage technology companies.